Late Effects of Cancer Treatment

Late Effects of Cancer Treatment

Late Effects of Cancer Treatment

On this page

Intro & Risks - Aftermath Aces

  • Late Effects: Health problems appearing ≥5 years after cancer treatment ends, or earlier if persistent/progressive.
  • Key Risk Factors:
    • Younger age at diagnosis (↑ vulnerability).
    • Genetic predisposition (e.g., Li-Fraumeni).
    • Treatment type & intensity:
      • Chemotherapy (agent, cumulative dose).
      • Radiotherapy (site, dose, volume).
      • Surgery, HSCT.
    • Primary cancer type.
  • 📌 ACES for Risks: Age, Cancer type/Chemo, Exposure (Radiation), Susceptibility (Genetic).

⭐ Childhood cancer survivors: >5x risk of severe chronic conditions by age 50 vs. siblings.

Childhood Cancer Survivors: Risk of Late Effectsoka

Systemic Effects - Organ Hit List

A summary of common late effects by organ system:

Organ SystemKey Causal Agents/TxMajor Late Effects
CardiacAnthracyclines (Doxorubicin), Cyclophosphamide, Chest RTCardiomyopathy (dose-dependent), CHF, Arrhythmias, CAD, Valvular disease, Pericarditis. Monitor with ECHO.
PulmonaryBleomycin, Busulfan, Carmustine (BCNU), Chest RTPneumonitis, Pulmonary fibrosis. Monitor with PFTs.
EndocrineCranial RT, Neck RT, Alkylating agents, TBIGH deficiency (most common), Hypothyroidism, Gonadal failure (infertility, POI), Adrenal insufficiency, Diabetes.
RenalCisplatin (📌 "splats" kidneys/ears), Carboplatin, Ifosfamide, High-dose MTX, RT↓GFR, Tubular damage (Fanconi - Ifosfamide), Glomerulopathy, Hypertension. Monitor U/A, Creatinine.
NeurocognitiveCranial RT (dose & age-dependent), IT MTX/Ara-C↓IQ, Learning disabilities, Memory/attention deficits, Leukoencephalopathy. Vinca alkaloids, Cisplatin: Peripheral neuropathy.
MusculoskeletalCorticosteroids, Methotrexate, RTOsteoporosis, Avascular necrosis (AVN), Growth retardation, Scoliosis, Soft tissue fibrosis.
GastrointestinalAbdominal RT, Anthracyclines, VincristineChronic enteritis, Malabsorption, Strictures, Esophagitis, Hepatic fibrosis/veno-occlusive disease (VOD).
Second CancersAlkylating agents, Etoposide, RTAML/MDS (peak 5-10 yrs), Solid tumors (e.g., sarcoma, breast, thyroid; peak >10 yrs).

Late effects of pediatric cancer treatment by diagnosis

Malignancies & Mind - Double Trouble

  • Second Malignant Neoplasms (SMNs):
    • Most common solid SMN: Thyroid cancer (post-radiation), Breast cancer.
    • Most common hematological SMN: Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome (MDS) (post-alkylating agents, etoposide).
    • Risk factors: Genetic predisposition (e.g., Li-Fraumeni), type/dose of therapy (radiation, alkylating agents, etoposide), younger age at treatment.
    • Screening: Lifelong surveillance based on primary cancer and treatment received.
  • Psychosocial Impact:
    • ↑ Risk: Anxiety, depression, PTSD, social isolation, academic difficulties, unemployment.
    • Body image issues, neurocognitive deficits (chemo brain).
    • Need for long-term psychological support & counseling.

⭐ Alkylating agents (e.g., cyclophosphamide) and epipodophyllotoxins (e.g., etoposide) are highly associated with therapy-related AML/MDS, often occurring 5-10 years post-treatment.

  • 📌 Alkylating Agents & Etoposide cause AML/MDS Eventually (AAE-AAE).

Surveillance & Care - Watch & Ward

  • Goal: Early detection & management of late effects; improve quality of life (QoL).
  • Risk-Stratified Care: Tailored by diagnosis, treatment (chemo, RT, surgery), age.
  • COG Guidelines: Standard for screening (echo, PFTs, mammograms).
  • Survivor Clinics: Multidisciplinary team (oncology, endocrine, cardio, psych).
  • Interventions:
    • Regular exams & history.
    • Organ-specific screening.
    • Vaccinations (key for immunosuppressed).
    • Lifestyle counseling (diet, exercise, no smoking).
    • Psychosocial support.

⭐ Hodgkin Lymphoma survivors (mantle RT): annual mammography + breast MRI from age 25 or 8 yrs post-RT (whichever later), not beyond age 40.

High‑Yield Points - ⚡ Biggest Takeaways

  • Secondary Malignancies: Significant risk of AML/MDS (alkylating agents, etoposide) and solid tumors post-radiation.
  • Cardiotoxicity: Anthracyclines (e.g., doxorubicin) induce dose-dependent cardiomyopathy; monitor closely.
  • Organ Toxicities: Bleomycin (pulmonary fibrosis); Cisplatin (nephrotoxicity, ototoxicity).
  • Endocrinopathies: Common include hypothyroidism, GH deficiency (cranial radiation), and gonadal dysfunction.
  • Neurocognitive Impairment: Frequent after cranial radiation and high-dose/intrathecal methotrexate.
  • Ifosfamide: Associated with hemorrhagic cystitis (prevent with MESNA) and renal Fanconi syndrome.

Practice Questions: Late Effects of Cancer Treatment

Test your understanding with these related questions

Cardiotoxicity caused by radiotherapy & chemotherapy is best detected by

1 of 5

Flashcards: Late Effects of Cancer Treatment

1/10

_____ system of staging is used for staging childhood non-Hodgkin lymphoma.

TAP TO REVEAL ANSWER

_____ system of staging is used for staging childhood non-Hodgkin lymphoma.

St Jude

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial